Quoin Pharmaceuticals (QNRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.90, -3.23% vs the prior close of $4.03.
- Volume 30.81K shares, 0.0x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
QNRX slides 3.2% to $3.90, a 3-month low, 8 down days in a row. Closed at $3.90, -3.23% vs the prior close of $4.03. Day range $3.90–$4.11, opened at $4.00.
QNRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — QNRX slides 3.2% to $3.90, a 3-month low, 8 down days in a row
- Closed at $3.90, -3.23% vs the prior close of $4.03. Day range $3.90–$4.11, opened at $4.00.
- Volume was 30.81K shares, 0.0x its 50-day average of 693.40K — lighter than usual.
- Price is -31.1% vs its 50-day average ($5.66) and -40.0% vs its 200-day average ($6.49).
- 52-week range $3.25–$23.50; today's close sits at 3% of that range, 83.4% below the 52-week high.
- That makes 8 straight losses.
Oct 15, 2026 — QNRX dips 1.7% to $4.03, a 3-month low, 7 down days in a row
- Closed at $4.03, -1.71% vs the prior close of $4.10. Day range $3.91–$4.15, opened at $3.95.
- Volume was 24.10K shares, 0.0x its 50-day average of 693.05K — lighter than usual.
- Price is -28.9% vs its 50-day average ($5.67) and -38.4% vs its 200-day average ($6.54).
- 52-week range $3.25–$23.50; today's close sits at 4% of that range, 82.9% below the 52-week high.
- That makes 7 straight losses.
Oct 14, 2026 — QNRX dips 1.2% to $4.10, a 3-month low, 6 down days in a row
- Closed at $4.10, -1.20% vs the prior close of $4.15. Day range $3.91–$4.29, opened at $4.11.
- Volume was 159.40K shares, 0.2x its 50-day average of 690.04K — lighter than usual.
- Price is -27.8% vs its 50-day average ($5.68) and -37.8% vs its 200-day average ($6.59).
- 52-week range $3.25–$23.50; today's close sits at 4% of that range, 82.6% below the 52-week high.
- That makes 6 straight losses.
- SEC filings that day: 8-K.
Oct 13, 2026 — QNRX slides 4.8% to $4.15, a 3-month low, 5 down days in a row
- Closed at $4.15, -4.82% vs the prior close of $4.36. Day range $4.15–$4.56, opened at $4.49.
- Volume was 26.40K shares, 0.0x its 50-day average of 689.87K — lighter than usual.
- Price is -27.0% vs its 50-day average ($5.68) and -37.5% vs its 200-day average ($6.64).
- 52-week range $3.25–$23.50; today's close sits at 4% of that range, 82.3% below the 52-week high.
- That makes 5 straight losses.
Oct 12, 2026 — QNRX slides 3.1% to $4.36, a 1-month low, 4 down days in a row
- Closed at $4.36, -3.11% vs the prior close of $4.50. Day range $4.30–$5.31, opened at $4.83.
- Volume was 50.60K shares, 0.1x its 50-day average of 689.00K — lighter than usual.
- Price is -23.4% vs its 50-day average ($5.69) and -34.9% vs its 200-day average ($6.69).
- 52-week range $3.25–$41.80; today's close sits at 3% of that range, 89.6% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — QNRX dips 1.1% to $4.50, 3 down days in a row
- Closed at $4.50, -1.10% vs the prior close of $4.55. Day range $4.25–$4.68, opened at $4.32.
- Volume was 42.50K shares, 0.1x its 50-day average of 688.96K — lighter than usual.
- Price is -20.9% vs its 50-day average ($5.69) and -33.2% vs its 200-day average ($6.74).
- 52-week range $3.25–$41.80; today's close sits at 3% of that range, 89.2% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — QNRX slides 3.2% to $4.55
- Closed at $4.55, -3.19% vs the prior close of $4.70. Day range $4.30–$4.70, opened at $4.49.
- Volume was 49.00K shares, 0.1x its 50-day average of 688.10K — lighter than usual.
- Price is -20.0% vs its 50-day average ($5.69) and -32.9% vs its 200-day average ($6.78).
- 52-week range $3.25–$41.80; today's close sits at 3% of that range, 89.1% below the 52-week high.
Oct 7, 2026 — QNRX dips 0.4% to $4.70
- Closed at $4.70, -0.42% vs the prior close of $4.72. Day range $4.50–$4.83, opened at $4.61.
- Volume was 26.20K shares, 0.0x its 50-day average of 687.75K — lighter than usual.
- Price is -17.3% vs its 50-day average ($5.68) and -31.2% vs its 200-day average ($6.83).
- 52-week range $3.25–$41.80; today's close sits at 4% of that range, 88.8% below the 52-week high.
Oct 6, 2026 — QNRX jumps 3.6% to $4.72
- Closed at $4.72, +3.62% vs the prior close of $4.55. Day range $4.35–$4.88, opened at $4.48.
- Volume was 103.40K shares, 0.2x its 50-day average of 685.84K — lighter than usual.
- Price is -16.8% vs its 50-day average ($5.67) and -31.4% vs its 200-day average ($6.88).
- 52-week range $3.25–$41.80; today's close sits at 4% of that range, 88.7% below the 52-week high.
Oct 5, 2026 — QNRX rises 1.9% to $4.55
- Closed at $4.55, +1.90% vs the prior close of $4.47. Day range $4.36–$4.74, opened at $4.53.
- Volume was 21.10K shares, 0.0x its 50-day average of 685.55K — lighter than usual.
- Price is -19.6% vs its 50-day average ($5.66) and -34.2% vs its 200-day average ($6.93).
- 52-week range $3.25–$41.80; today's close sits at 3% of that range, 89.1% below the 52-week high.
Oct 2, 2026 — QNRX slides 5.3% to $4.47, a 1-month low
- Closed at $4.47, -5.30% vs the prior close of $4.72. Day range $4.47–$4.81, opened at $4.81.
- Volume was 20.30K shares, 0.0x its 50-day average of 685.33K — lighter than usual.
- Price is -21.0% vs its 50-day average ($5.66) and -35.8% vs its 200-day average ($6.96).
- 52-week range $3.25–$41.80; today's close sits at 3% of that range, 89.3% below the 52-week high.
- SEC filings that day: DEF 14A.
QNRX latest news & SEC filings
Every SEC filing by or about QNRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 2, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Sep 25, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 25, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 22, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 18, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Carter Denise P. bought 20,490 shares at $4.88 (≈$99.99K) on Aug 31, 2026
- Carter Denise P. bought 20,490 shares at $4.88 (≈$99.99K) on Aug 31, 2026
- Carter Denise P. bought 20,490 shares at $4.88 (≈$99.99K) on Aug 31, 2026
- Carter Denise P. bought 20,490 shares at $4.88 (≈$99.99K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Myers Michael bought 20,490 shares at $4.88 (≈$99.99K) on Aug 31, 2026
- Myers Michael bought 20,490 shares at $4.88 (≈$99.99K) on Aug 31, 2026
- Myers Michael bought 20,490 shares at $4.88 (≈$99.99K) on Aug 31, 2026
- Myers Michael bought 20,490 shares at $4.88 (≈$99.99K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lawlor Sally Bridget bought 10,244 shares at $4.88 (≈$49.99K) on Aug 31, 2026
- Lawlor Sally Bridget bought 10,244 shares at $4.88 (≈$49.99K) on Aug 31, 2026
- Lawlor Sally Bridget bought 10,244 shares at $4.88 (≈$49.99K) on Aug 31, 2026
- Lawlor Sally Bridget bought 10,244 shares at $4.88 (≈$49.99K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Culverwell Anthony James bought 6,146 shares at $4.88 (≈$29.99K) on Aug 31, 2026
- Culverwell Anthony James bought 6,146 shares at $4.88 (≈$29.99K) on Aug 31, 2026
- Culverwell Anthony James bought 6,146 shares at $4.88 (≈$29.99K) on Aug 31, 2026
- Culverwell Anthony James bought 6,146 shares at $4.88 (≈$29.99K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade QNRX
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.95% (largest 18.2%). That is a volatile stock.
- Liquidity: about 50.79K shares (≈$198.08K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.90 vs a range of $3.25–$23.50 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:35 on Apr 9, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 20 open-market buys, 0 sales; latest: Anthony James Culverwell bought 6,146 shares on Aug 31, 2026.
- Latest filings: 8-K Oct 14, 2026; 8-K Sep 22, 2026; 8-K Sep 10, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
QNRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 4.00 | 4.11 | 3.90 | 3.90 | 30.81K |
| Oct 15, 2026 | 3.95 | 4.15 | 3.91 | 4.03 | 24.10K |
| Oct 14, 2026 | 4.11 | 4.29 | 3.91 | 4.10 | 159.40K |
| Oct 13, 2026 | 4.49 | 4.56 | 4.15 | 4.15 | 26.40K |
| Oct 12, 2026 | 4.83 | 5.31 | 4.30 | 4.36 | 50.60K |
| Oct 9, 2026 | 4.32 | 4.68 | 4.25 | 4.50 | 42.50K |
| Oct 8, 2026 | 4.49 | 4.70 | 4.30 | 4.55 | 49.00K |
| Oct 7, 2026 | 4.61 | 4.83 | 4.50 | 4.70 | 26.20K |
| Oct 6, 2026 | 4.48 | 4.88 | 4.35 | 4.72 | 103.40K |
| Oct 5, 2026 | 4.53 | 4.74 | 4.36 | 4.55 | 21.10K |
| Oct 2, 2026 | 4.81 | 4.81 | 4.47 | 4.47 | 20.30K |
| Oct 1, 2026 | 4.68 | 4.80 | 4.50 | 4.72 | 17.10K |
| Sep 30, 2026 | 4.88 | 5.09 | 4.55 | 4.56 | 139.20K |
| Sep 29, 2026 | 5.30 | 5.52 | 4.80 | 4.88 | 64.20K |
| Sep 28, 2026 | 6.40 | 6.41 | 5.26 | 5.26 | 70.30K |
| Sep 25, 2026 | 6.40 | 6.69 | 6.25 | 6.43 | 11.00K |
| Sep 24, 2026 | 6.83 | 7.10 | 6.12 | 6.38 | 39.40K |
| Sep 23, 2026 | 7.07 | 7.15 | 6.51 | 6.75 | 39.40K |
| Sep 22, 2026 | 6.98 | 7.16 | 6.91 | 7.01 | 29.30K |
| Sep 21, 2026 | 6.92 | 7.14 | 6.76 | 6.90 | 52.10K |
About Quoin Pharmaceuticals
Quoin Pharmaceuticals (QNRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in ASHBURN, VA. State of incorporation: Israel. Fiscal year ends —. SEC CIK 1671502.
QNRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Denise P. Carter | Chief Operating Officer | Sep 1, 2026 |
| Joseph Patrick Cooper | Director | Feb 6, 2026 |
| Anthony James Culverwell | Director | Sep 1, 2026 |
| Dennis Langer | Director | Aug 28, 2026 |
| Natalie Ee Mun Leong | Director | Feb 6, 2026 |
| Michael Myers | Chief Executive Officer | Sep 1, 2026 |
| Michael T Sember | Director | Feb 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Denise P. Carter | Chief Operating Officer | Sep 1, 2026 |
| Sally Bridget Lawlor | Chief Financial Officer | Sep 1, 2026 |
| Michael Myers | Chief Executive Officer | Sep 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 31, 2026 | Anthony James Culverwell | Buy | 6,146 | $4.88 |
| Aug 31, 2026 | Anthony James Culverwell | Buy | 6,146 | $4.88 |
| Aug 31, 2026 | Anthony James Culverwell | Buy | 6,146 | $4.88 |
| Aug 31, 2026 | Anthony James Culverwell | Buy | 6,146 | $4.88 |
| Aug 31, 2026 | Michael Myers | Buy | 20,490 | $4.88 |
| Aug 31, 2026 | Michael Myers | Buy | 20,490 | $4.88 |
| Aug 31, 2026 | Michael Myers | Buy | 20,490 | $4.88 |
| Aug 31, 2026 | Michael Myers | Buy | 20,490 | $4.88 |
| Aug 31, 2026 | Sally Bridget Lawlor | Buy | 10,244 | $4.88 |
| Aug 31, 2026 | Sally Bridget Lawlor | Buy | 10,244 | $4.88 |
| Aug 31, 2026 | Sally Bridget Lawlor | Buy | 10,244 | $4.88 |
| Aug 31, 2026 | Sally Bridget Lawlor | Buy | 10,244 | $4.88 |
| Aug 31, 2026 | Denise P. Carter | Buy | 20,490 | $4.88 |
| Aug 31, 2026 | Denise P. Carter | Buy | 20,490 | $4.88 |
| Aug 31, 2026 | Denise P. Carter | Buy | 20,490 | $4.88 |
QNRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-15.80M | — | $-13.54M |
| Dec 31, 2024 | — | $-8.96M | — | $-7.86M |
| Dec 31, 2023 | — | $-8.69M | — | $-7.86M |
| Dec 31, 2022 | — | $-9.38M | — | $-8.48M |
| Dec 31, 2021 | — | $-21.46M | — | $-5.72M |
Latest balance sheet: total assets $11.97M, total liabilities $8.04M, cash $3.85M (as of Jun 30, 2026).
QNRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $5.09 |
| May 7, 2026 | 8-K Item 2.02 (results) | $6.37 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $7.57 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $8.57 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $6.91 |
| May 14, 2025 | 8-K Item 2.02 (results) | $7.65 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $10.32 |
| Nov 8, 2024 | 8-K Item 2.02 (results) | $23.45 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 13, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
| Aug 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on QNRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.